Results 111 to 120 of about 709,109 (292)

Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome

British Journal of Clinical Pharmacology, EarlyView.
Aim This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids.
Maren Hermanns‐Clausen, Michaela Sommer, Annette Zschiesche, Verena Angerer, Martin Scheu, Florian Eyer, Johannes Nadler, Volker Auwärter   +7 more
wiley   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source

Serotonin and the control of eupneic breathing

, 2018
The mechanisms responsible for respiratory rhythm and pattern generation are continuously tuned by neuromodulators. Serotonin is a powerful modulator of the respiratory network that regulates synaptic and intrinsic properties of respiratory neurons that,
Zoccal, Daniel B. [UNESP]
core   +1 more source

Applying machine learning to pharmacovigilance data: A proof‐of‐concept study

British Journal of Clinical Pharmacology, EarlyView.
Aim Machine learning (ML) applications in pharmacovigilance remain limited and underexplored. Using data from the French National pharmacovigilance database (FNPV), this proof‐of‐concept study aimed to assess the feasibility of using a ML algorithm—eXtreme Gradient Boosting (XGBoost)—combined with SHapley Additive exPlanations (SHAP) analysis, to ...
Romain Barus, Pauline Schiro, Jean‐Luc Faillie, Romane Freppel, Johana Béné, Claire de Canecaude, François Montastruc   +6 more
wiley   +1 more source

Gabapentinoids‐duloxetine combination therapy for chronic pain: A mechanism oriented rational to bridge theoretical knowledge and real life setting

British Journal of Clinical Pharmacology, EarlyView.
Chronic pain represents a complex debilitating condition that extends beyond the protective function of physiological pain, often persisting as an independent disease entity. Chronic primary and secondary pain syndromes reflect a multifaceted continuum involving nociceptive, neuropathic and nociplastic mechanisms.
Stefania Nobili, Maurizio Evangelista, Elena Lucarini, Elena G. Giugliano, Carla Ghelardini, Laura Micheli, Lorenzo Di Cesare Mannelli   +6 more
wiley   +1 more source

Serotonin regulation of mitochondria in kidney diseases

Pharmacological Research
Serotonin, while conventionally recognized as a neurotransmitter in the CNS, has recently gained attention for its role in the kidney. Specifically, serotonin is not only synthesized in the kidney, but it also regulates glomerular function, vascular ...
Kevin Hurtado, Natalie E. Scholpa, Jennifer G. Schnellmann, Rick G. Schnellmann   +3 more
doaj   +1 more source

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

British Journal of Clinical Pharmacology, EarlyView.
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask, Miina Lamminmäki, Olli Kampman, Mari Hämäläinen, Eeva Moilanen, Niko Seppälä, Anssi Solismaa   +6 more
wiley   +1 more source

5-HT(2B) receptors are required for serotonin-selective antidepressant actions.

, 2012
International audienceThe therapeutic effects induced by serotonin-selective reuptake inhibitor (SSRI) antidepressants are initially triggered by blocking the serotonin transporter and rely on long-term adaptations of pre- and post-synaptic receptors. We
Roumier, A., Boutourlinsky, Katia, Diaz, S. L., Narboux-Nême, Nicolas, Moutkine, Imane, Belmer, Arnauld, Fernández, Sébasatien, Doly, S., Maroteaux, L., Diaz, Silviana Laura, Banas, Sophie Marie, Fernandez, S., Narboux-Nême, N., Roumier, Anne, Maroteaux, Luc, Belmer, A., Doly, Stéphane, Mazot, P., Banas, S. M., Mazot, Pierre, Boutourlinsky, K., Moutkine, I.   +21 more
core   +1 more source

Exposure to CYP2C19‐metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 2C19 (CYP2C19) genotype testing is recommended to guide antiplatelet selection after ischaemic stroke and transient ischaemic attack. CYP2C19 also metabolizes several commonly prescribed non‐antiplatelet drugs. We aimed to quantify exposure to CYP2C19‐metabolized drugs in stroke patients at hospital discharge and during ...
Cleodie C. Swire, Andrew T. Lambarth, Ayesha Saleem, Daniel R. Burrage   +3 more
wiley   +1 more source

Glucocorticoid exposure and initiation of SSRIs among patients with rheumatoid arthritis: A nested case–control study in UK primary care

British Journal of Clinical Pharmacology, EarlyView.
Aim The immune system might affect the development of anxiety disorders, though mechanisms remain unclear. This nested case–control study investigates whether use of glucocorticoids, potent immunosuppressants, is associated with SSRI initiation (a proxy for pharmacologically treated mental disorders, predominantly depression and/or anxiety).
Elise J. Heesbeen, Patrick C. Souverein, Eibert R. Heerdink, Elisabeth Y. Bijlsma, Lucianne Groenink   +4 more
wiley   +1 more source